Browse by author
Lookup NU author(s): Dr Ian Griffiths
This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).
© 2017 BMJ Publishing Group Ltd & European League Against Rheumatism. Objectives Patients with rheumatoid arthritis (RA) are at increased risk of myocardial infarction (MI) compared with subjects without RA, with the increased risk driven potentially by inflammation. Tumour necrosis factor inhibitors (TNFi) may modulate the risk and severity of MI. We compared the risk and severity of MI in patients treated with TNFi with that in those receiving synthetic disease-modifying antirheumatic drugs (sDMARDs). Methods This analysis included patients with RA recruited from 2001 to 2009 to the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis starting TNFi (etanercept/infliximab/adalimumab) and a biologic-naïve comparator cohort receiving sDMARD. All patients were followed via physician and patient questionnaires and national death register linkage. Additionally, all patients were linked to the Myocardial Ischaemia National Audit Project, a national registry of hospitalisations for MI. Patients were censored at first verified MI, death, 90 days following TNFi discontinuation, last physician follow-up or 20 April 2010, whichever came first. The risk of first MI was compared between cohorts using COX regression, adjusted with propensity score deciles (PD). MI phenotype and severity were compared using descriptive statistics. 6-month mortality post MI was compared using logistic regression. Results 252 verified first MIs were analysed: 58 in 3058 patients receiving sDMARD and 194 in 11 200 patients receiving TNFi (median follow-up per person 3.5 years and 5.3 years, respectively). The PD-adjusted HR of MI in TNFi referent to sDMARD was 0.61 (95% CI 0.41 to 0.89). No statistically significant differences in MI severity or mortality were observed between treatment groups. Conclusions Patients with RA receiving TNFi had a decreased risk of MI compared with patients with RA receiving sDMARD therapy over the medium term. This might be attributed to a direct action of TNFi on the atherosclerotic process or better overall disease control.
Author(s): Low ASL, Symmons DPM, Lunt M, Mercer LK, Gale CP, Watson KD, Dixon WG, Hyrich KL, Maiden N, Price T, Hopkinson N, O'Reilly S, Hordon L, Griffiths I, Porter D, Capell H, Hassell A, Benitha R, Choy E, Walsh D, Emery P, Knight S, Bruce I, Taggart A, Scott D, Thompson P, McCrae F, Goodfellow R, Kitas G, Jubb R, Abernethy R, Clarke S, Green S, Sanders P, Coulson A, Harrison B, Bukhari M, Klimiuk P
Publication type: Article
Publication status: Published
Journal: Annals of the Rheumatic Diseases
Year: 2017
Volume: 76
Pages: 654-660
Print publication date: 01/04/2017
Online publication date: 10/03/2017
Acceptance date: 12/08/2016
Date deposited: 04/05/2017
ISSN (print): 0003-4967
ISSN (electronic): 1468-2060
Publisher: BMJ Publishing Group
URL: https://doi.org/10.1136/annrheumdis-2016-209784
DOI: 10.1136/annrheumdis-2016-209784
Altmetrics provided by Altmetric
